PARSD Pharmos (MM)

Pharmos Corporation (NasdaqSC: PARSD) will present at the following forum: -0- *T What: Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum When: June 15, 2005 @ 2:35 PM Eastern Time Sponsors: Barron's, The Wall Street Journal, The American Stock Exchange and Business Wire Keynote Presentations: Lynn Sutherland, M.S., M.B.A. - President, Sutherland Consulting Dr. Navdeep Jaikaria, Senior Biotechnology Analyst, Rodman & Renshaw, LLC Where: The Princeton Club of New York, 15 West 43rd Street., New York City, NY 10036 How to attend: Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.informedinvestors.com/CustomEvent/89559/index.asp If you are unable to attend the live event, the forum will be available via webcast at http://www.informedinvestors.com/CustomEvent/89559/index.asp Contact: Gale Smith, Gale.Smith@pharmos-us.com, 732-452-9556 X204 *T Pharmos discovers and develops novel therapeutics to treat a range of indications, in particular neurological and inflammatory disorders. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor, the lead CB2-selective receptor agonist candidate, is scheduled to begin Phase I safety studies in the second half of 2005 and, if successful, enter Phase II testing in pain indications around yearend or early 2006. From the dextrocannabinoid family, the neuroprotective drug candidate dexanabinol recently completed a Phase IIa trial as a preventive agent against post-surgical cognitive impairment. Other compounds from Pharmos' proprietary synthetic cannabinoid library are in pre-clinical studies targeting pain, multiple sclerosis, rheumatoid arthritis and other disorders.